- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Severe active juvenile idiopathic arthritis Severe active rheumatoid arthritis Systemic juvenile idiopathic arthritis Active giant cell arteritis
- Meeting Date: November 2025
- Public Summary Document (PSD) November 2025 PBAC Meeting - (PDF 838.9KB)
- Public Summary Document (PSD) November 2025 PBAC Meeting - (Word 143.0KB)
Tocilizumab – November 2025
Tocilizumab: Concentrate for injection 80 mg in 4 mL Concentrate for injection 200 mg in 10 mL Concentrate for injection 400 mg in 20 mL Injection 162 mg in 0.9 mL single use pre-filled pen Injection 162 mg in 0.9 mL single use pre-filled syringe; Avtozma® - November 2025
Last updated
5 November 2025
